Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[1] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
Tsilimigras, Diamantis I.
Moris, Dimitrios
JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
[2] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
Hoang, H. T.
ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
[3] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
Cheon, Jaekyung
Yoo, Changhoon
Hong, Jung Yong
Kim, Han Sang
Lee, Dae-Won
Lee, Myung Ah
Kim, Jin Won
Kim, Ilhwan
Oh, Sang-Bo
Hwang, Jun-Eul
Chon, Hong Jae
Lim, Ho Yeong
LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
[4] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
Cappuyns, Sarah
Pique-Gili, Marta
Esteban-Fabro, Roger
Philips, Gino
Pinyol, Roser
Vandecaveye, Vincent
Abril-Fornaguera, Jordi
Haber, Philipp
Verslype, Chris
Van Cutsem, Eric
Lambrechts, Diether
Villanueva, Augusto
Dekervel, Jeroen
Llovet, Josep M.
HEPATOLOGY, 2023, 78 : S1871 - S1872
[5] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Kariyama, Kazuya
Tani, Joji
Hirooka, Masashi
Takaguchi, Koichi
Atsukawa, Masanori
Fukunishi, Shinya
Itobayashi, Ei
Tsuji, Kunihiko
Tajiri, Kazuto
Ochi, Hironori
Ishikawa, Toru
Yasuda, Satoshi
Ogawa, Chikara
Toyoda, Hidenori
Hatanaka, Takeshi
Nishimura, Takashi
Kakizaki, Satoru
Kawata, Kazuhito
Shimada, Noritomo
Tada, Fujimasa
Nouso, Kazuhiro
Tsutsui, Akemi
Ohama, Hideko
Morishita, Asahiro
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Kosaka, Hisashi
Imai, Michitaka
Naganuma, Atsushi
Nakamura, Shinichiro
Koizumi, Yohei
Matono, Tomomitsu
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
ONCOLOGY, 2023, 101 (04) : 270 - 281
[6] Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients
Kim, Hyeyeong
Cheon, Jaekyung
Ha, Yeongjung
Kim, Han Sang
Kim, Chang Gon
Kim, Ilhwan
Kim, Chan
Jung, Sang-Hoon
Chon, Hong Jae
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[7] Combination of Radiotherapy and Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study
Hur, Y. J.
Kim, J.
Seong, J.
Lee, C. K.
Kim, B. K.
Kim, D. Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E304 - E305
[8] Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma
Cheon, Jaekyung
Kim, Hyeyeong
Kim, Han Sang
Kim, Chang Gon
Kim, Ilhwan
Kang, Beodeul
Kim, Chan
Jung, Sanghoon
Ha, Yeonjung
Chon, Hong Jae
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[9] Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Kobayashi, Kazufumi
Ogasawara, Sadahisa
Ishino, Takamasa
Unozawa, Hidemi
Nakagawa, Miyuki
Fujiwara, Kisako
Sakuma, Takafumi
Fujita, Naoto
Kanzaki, Hiroaki
Koroki, Keisuke
Nakamura, Masato
Kiyono, Soichiro
Kanogawa, Naoya
Kondo, Takayuki
Saito, Tomoko
Nakagawa, Ryo
Nakamoto, Shingo
Muroyama, Ryosuke
Chiba, Tetsuhiro
Kato, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
Sinner, Friedrich
Pinter, Matthias
Scheiner, Bernhard
Ettrich, Thomas Jens
Sturm, Niklas
Gonzalez-Carmona, Maria A.
Waidmann, Oliver
Finkelmeier, Fabian
Himmelsbach, Vera
De Toni, Enrico N.
Ben Khaled, Najib
Mohr, Raphael
Fruendt, Thorben Wilhelm
Kuetting, Fabian
van Boemmel, Florian
Lieb, Sabine
Krug, Sebastian
Bettinger, Dominik
Schultheiss, Michael
Jochheim, Leonie S.
Best, Jan
Mueller, Christian
Keitel, Verena
Venerito, Marino
CANCERS, 2022, 14 (23)

← 1 2 3 4 5 →